8-K: Citius Pharmaceuticals Secures $6 Million in Registered Direct Offering to Fund LYMPHIR Launch and Pipeline Development

Citius Pharmaceuticals Inc. has successfully closed a registered direct offering, raising approximately $6 million in gross proceeds, with potential for an additional $9.8 million from warrant exercises, to support the commercial launch of its FDA-approved drug LYMPHIR and advance its pipeline.

Summary

• Citius Pharmaceuticals, Inc. entered into a securities purchase agreement on June 9, 2025, for a registered direct offering.
• The offering included the issuance and sale of 540,000 shares of common stock at $1.22 per share and 4,380,000 pre-funded warrants at $1.2199 per pre-funded warrant, totaling 4,920,000 units.
• The Company also issued warrants to purchase up to 9,840,000 shares of common stock, exercisable immediately at $1.00 per share, expiring 24 months after issuance.
• Pre-funded warrants are exercisable immediately at a nominal price of $0.0001 per share and remain valid until fully exercised.
• The offering closed on June 11, 2025, generating approximately $6.0 million in gross proceeds.
• Net proceeds are expected to be approximately $5,455,000 after deducting placement agent fees and other offering expenses.
• H.C. Wainwright and Co., LLC acted as the exclusive placement agent, receiving a 7.0% cash fee of gross proceeds, plus reimbursements up to $50,000 for legal counsel, $35,000 for non-accountable expenses, and $15,950 for a clearing fee.
• The placement agent was also granted warrants to purchase up to 344,400 shares of common stock at an exercise price of $1.525 per share.
• The Company anticipates using the net proceeds to support the commercial launch of LYMPHIR, including milestone, regulatory, and other payments, and for general corporate purposes.
• Potential additional gross proceeds of approximately $9.8 million could be realized if all short-term warrants are fully exercised on a cash basis, though no assurance is given for their exercise.

Sentiment

Score: 6

Explanation: The capital raise provides essential funding for the commercial launch of LYMPHIR and continued pipeline development, which is a positive step for a biopharmaceutical company. However, the significant dilution from the shares and warrants, coupled with the low warrant exercise price and the implied ongoing need for capital (as suggested by the Nasdaq compliance risk and the ATM exception), temper the overall positive sentiment. It's a necessary financing but comes with a cost to existing shareholders.

Positives

• Successfully secured approximately $6.0 million in gross proceeds, providing capital for immediate operational needs.
• The funding is specifically allocated to support the commercial launch of LYMPHIR, an FDA-approved targeted immunotherapy, indicating progress towards revenue generation.
• The offering includes potential for an additional $9.8 million in gross proceeds from the exercise of short-term warrants, offering future funding flexibility.
• The company's late-stage pipeline assets, Mino-Lok and CITI-002 (Halo-Lido), have completed pivotal trials with Mino-Lok meeting its primary and secondary endpoints, suggesting positive clinical development progress.

Negatives

• The offering involves significant dilution through the issuance of 4,920,000 shares/pre-funded warrants and an additional 9,840,000 common warrants, which could negatively impact existing shareholder value.
• The common warrants have an exercise price of $1.00 per share, which is below the offering price of $1.22, potentially leading to further dilution at a lower valuation if exercised.
• Substantial placement agent fees and expenses totaling approximately $520,950 were incurred, reducing the net proceeds available to the company.
• The company's agreement not to issue new equity for 60 days, with an exception for 'at-the-market' offerings at or above $1.75 after 30 days, suggests a potential ongoing need for capital and future dilution risk.

Risks

• The company has a stated need for substantial additional funds to support its operations.
• There is no assurance that the company will be able to raise additional money to fund its operations for at least the next 12 months as a going concern.
• Uncertainty exists regarding the company's ability to successfully commercialize LYMPHIR and any other product candidates that may be approved by the FDA.
• There is a risk related to Citius Pharma's ability to regain compliance with Nasdaq's continued listing requirements.
• Risks are associated with the results of research and development activities, including those from existing and new pipeline assets.
• The company faces risks related to research using its assets but conducted by third parties.
• Uncertainties exist regarding the estimated markets for product candidates and their acceptance by the market.
• Dependence on third-party suppliers and the ability to procure cGMP commercial-scale supply pose risks.
• The company's ability to obtain, perform under, and maintain financing and strategic agreements and relationships is a risk factor.
• Uncertainties relating to preclinical and clinical testing, and the early stage of products under development, are present.
• General market and other conditions, as well as risks related to the company's growth strategy, could negatively impact the business.
• Patent and intellectual property matters, including the ability to protect and enforce rights, are ongoing risks.
• The ability to identify, acquire, close, and integrate product candidates and companies successfully and on a timely basis is a challenge.
• Government regulation and competition in the biopharmaceutical industry pose significant risks.
• Future public health risks could further impact the company's business.
• There is no assurance that the short-term warrants issued in the offering will be exercised, limiting potential additional proceeds.

Future Outlook

The Company intends to use the net proceeds from the offering primarily to support the commercial launch of LYMPHIR, including associated milestone, regulatory, and other payments. Additionally, funds will be allocated for general corporate purposes. Citius Pharma is also actively engaging with the FDA to determine the next steps for its Mino-Lok and Halo-Lido programs, following the completion of their respective Phase 3 and Phase 2b trials.

Management Comments

• "The Company currently intends to use the net proceeds from the offering to support the commercial launch of LYMPHIR, including milestone, regulatory and other payments, as well as for general corporate purposes."

Industry Context

This registered direct offering by Citius Pharmaceuticals is a common financing strategy for biopharmaceutical companies, particularly those transitioning from clinical development to commercialization. With the recent FDA approval of LYMPHIR, securing capital is crucial for funding the commercial launch, which involves significant marketing, distribution, and regulatory expenses. The inclusion of warrants is also typical in such offerings, providing additional potential capital in the future while offering investors upside participation. The 'at-the-market' pricing suggests the company aimed to raise capital efficiently without a substantial discount, reflecting current market conditions for its stock.

Comparison to Industry Standards

• Registered direct offerings are a standard capital raising mechanism for small to mid-cap biopharmaceutical companies, especially those with late-stage or recently approved products, to fund commercialization efforts and ongoing R&D.
• The placement agent fee of 7.0% is within the typical range (often 5-10%) for such offerings in the biotech sector, reflecting standard compensation for investment banks facilitating these transactions.
• The issuance of warrants alongside shares is a common feature to make offerings more attractive to investors, providing additional upside potential. The exercise price of $1.00 for the common warrants, which is below the offering price of $1.22, is a notable term that provides immediate in-the-money value to warrant holders, which can be more aggressive than some industry benchmarks where warrant exercise prices are set at a premium to the offering price.
• The 'at-the-market' pricing, as stated, indicates the offering was priced close to the prevailing market price, which is generally viewed more favorably than deeply discounted private placements, as it minimizes immediate price disruption and reflects a more efficient market transaction.

Stakeholder Impact

• Shareholders will experience significant dilution due to the issuance of new common stock and warrants, potentially impacting per-share value.
• The capital raise provides crucial funding for the commercialization of LYMPHIR, which could lead to future revenue and potentially benefit shareholders if successful.
• The funds will support the company's operations and ongoing development of its pipeline, benefiting employees and potentially future customers through product availability.
• The company's ability to meet its financial obligations to suppliers and creditors is enhanced by the additional capital.

Next Steps

• Support the commercial launch of LYMPHIR, including milestone, regulatory, and other payments.
• Utilize net proceeds for general corporate purposes.
• Engage with the FDA to outline next steps for the Mino-Lok and Halo-Lido programs following trial completions.
• Maintain listing or quotation of Common Stock on Nasdaq and apply to list all newly issued shares and warrant shares.
• Comply with Nasdaq's continued listing requirements.

Key Dates

Recommendation

Keywords

Citius Pharmaceuticals, CTXR, Registered Direct Offering, Capital Raise, Biopharmaceutical, LYMPHIR, Mino-Lok, Halo-Lido, Warrants, Pre-funded Warrants, SEC Filing, 8-K, Dilution, Commercialization, Clinical Trials, FDA Approval, Nasdaq